Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

How is alpha-synuclein cleared from the cell?

Stefanis L, Emmanouilidou E, Pantazopoulou M, Kirik D, Vekrellis K, Tofaris GK.

J Neurochem. 2019 Sep;150(5):577-590. doi: 10.1111/jnc.14704. Epub 2019 May 8. Review.

PMID:
31069800
2.

Enhanced Dopamine in Prodromal Schizophrenia (EDiPS): a new animal model of relevance to schizophrenia.

Petty A, Cui X, Tesiram Y, Kirik D, Howes O, Eyles D.

NPJ Schizophr. 2019 Mar 29;5(1):6. doi: 10.1038/s41537-019-0074-z.

3.

Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs.

Lillethorup TP, Glud AN, Alstrup AKO, Noer O, Nielsen EHT, Schacht AC, Landeck N, Kirik D, Orlowski D, Sørensen JCH, Doudet DJ, Landau AM.

Sci Rep. 2018 Oct 24;8(1):15715. doi: 10.1038/s41598-018-34084-5.

4.

Quantification of Total and Mutant Huntingtin Protein Levels in Biospecimens Using a Novel alphaLISA Assay.

Baldo B, Sajjad MU, Cheong RY, Bigarreau J, Vijayvargia R, McLean C, Perrier AL, Seong IS, Halliday G, Petersén Å, Kirik D.

eNeuro. 2018 Oct 10;5(4). pii: ENEURO.0234-18.2018. doi: 10.1523/ENEURO.0234-18.2018. eCollection 2018 Jul-Aug.

5.

SIRT1 is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington disease.

Baldo B, Gabery S, Soylu-Kucharz R, Cheong RY, Henningsen JB, Englund E, McLean C, Kirik D, Halliday G, Petersén Å.

Neuropathol Appl Neurobiol. 2019 Jun;45(4):361-379. doi: 10.1111/nan.12514. Epub 2018 Aug 29.

PMID:
30019499
6.

In vivo quantification of glial activation in minipigs overexpressing human α-synuclein.

Lillethorup TP, Glud AN, Landeck N, Alstrup AKO, Jakobsen S, Vang K, Doudet DJ, Brooks DJ, Kirik D, Hinz R, Sørensen JC, Landau AM.

Synapse. 2018 Dec;72(12):e22060. doi: 10.1002/syn.22060. Epub 2018 Aug 12.

PMID:
30009467
7.

Preserved Function of Afferent Parvalbumin-Positive Perisomatic Inhibitory Synapses of Dentate Granule Cells in Rapidly Kindled Mice.

Hansen MG, Ledri LN, Kirik D, Kokaia M, Ledri M.

Front Cell Neurosci. 2018 Jan 9;11:433. doi: 10.3389/fncel.2017.00433. eCollection 2017.

8.

Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates.

Mandel RJ, Marmion DJ, Kirik D, Chu Y, Heindel C, McCown T, Gray SJ, Kordower JH.

Acta Neuropathol Commun. 2017 Jun 16;5(1):47. doi: 10.1186/s40478-017-0451-7.

9.

Toxic effects of human and rodent variants of alpha-synuclein in vivo.

Landeck N, Buck K, Kirik D.

Eur J Neurosci. 2017 Feb;45(4):536-547. doi: 10.1111/ejn.13493. Epub 2017 Jan 11.

PMID:
27893183
10.

Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands.

Kirik D, Cederfjäll E, Halliday G, Petersén Å.

Neurobiol Dis. 2017 Jan;97(Pt B):179-188. doi: 10.1016/j.nbd.2016.09.008. Epub 2016 Sep 8. Review.

PMID:
27616425
11.

Interaction between subclinical doses of the Parkinson's disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats.

Naughton C, O'Toole D, Kirik D, Dowd E.

Behav Brain Res. 2017 Jan 1;316:160-168. doi: 10.1016/j.bbr.2016.08.056. Epub 2016 Aug 29.

PMID:
27585560
12.

A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein.

Landeck N, Hall H, Ardah MT, Majbour NK, El-Agnaf OM, Halliday G, Kirik D.

Mol Neurodegener. 2016 Aug 22;11(1):61. doi: 10.1186/s13024-016-0125-0.

13.

How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?

Volpicelli-Daley LA, Kirik D, Stoyka LE, Standaert DG, Harms AS.

J Neurochem. 2016 Oct;139 Suppl 1:131-155. doi: 10.1111/jnc.13627. Epub 2016 May 4. Review.

14.

Assessment of brain metabolite correlates of adeno-associated virus-mediated over-expression of human alpha-synuclein in cortical neurons by in vivo (1) H-MR spectroscopy at 9.4 T.

Cuellar-Baena S, Landeck N, Sonnay S, Buck K, Mlynarik V, In 't Zandt R, Kirik D.

J Neurochem. 2016 Jun;137(5):806-19. doi: 10.1111/jnc.13547. Epub 2016 Feb 17.

15.

Overexpression of α-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity.

Kuzdas-Wood D, Fellner L, Premstaller M, Borm C, Bloem B, Kirik D, Wenning GK, Stefanova N.

BMC Neurosci. 2015 Dec 2;16:86. doi: 10.1186/s12868-015-0227-6.

16.

A doctor's dilemma.

Kirik D, Pain E.

Science. 2015 Nov 20;350(6263):998. doi: 10.1126/science.350.6263.998.

PMID:
26586764
17.

Hypothalamic overexpression of mutant huntingtin causes dysregulation of brown adipose tissue.

Soylu-Kucharz R, Adlesic N, Baldo B, Kirik D, Petersén Å.

Sci Rep. 2015 Sep 30;5:14598. doi: 10.1038/srep14598.

18.

Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function.

Buck K, Landeck N, Ulusoy A, Majbour NK, El-Agnaf OM, Kirik D.

Neurobiol Dis. 2015 Jun;78:100-14. doi: 10.1016/j.nbd.2015.03.008. Epub 2015 Mar 25.

PMID:
25818009
19.

Selective loss of oxytocin and vasopressin in the hypothalamus in early Huntington disease: a case study.

Gabery S, Halliday G, Kirik D, Englund E, Petersén Å.

Neuropathol Appl Neurobiol. 2015 Oct;41(6):843-8. doi: 10.1111/nan.12236. Epub 2015 Jun 2. No abstract available.

PMID:
25765897
20.

Volumetric analysis of the hypothalamus in Huntington Disease using 3T MRI: the IMAGE-HD Study.

Gabery S, Georgiou-Karistianis N, Lundh SH, Cheong RY, Churchyard A, Chua P, Stout JC, Egan GF, Kirik D, Petersén Å.

PLoS One. 2015 Feb 6;10(2):e0117593. doi: 10.1371/journal.pone.0117593. eCollection 2015.

21.

Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease.

Cederfjäll E, Broom L, Kirik D.

Mol Ther. 2015 May;23(5):896-906. doi: 10.1038/mt.2015.8. Epub 2015 Jan 16.

22.

Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.

Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K, Thompson L, Halliday G, Kirik D.

Brain. 2014 Sep;137(Pt 9):2493-508. doi: 10.1093/brain/awu193. Epub 2014 Jul 24.

PMID:
25062696
23.

Twisting mice move the dystonia field forward.

Petersén A, Kirik D.

J Clin Invest. 2014 Jul;124(7):2848-50. doi: 10.1172/JCI76624. Epub 2014 Jun 17.

24.

Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.

Sahin G, Thompson LH, Lavisse S, Ozgur M, Rbah-Vidal L, Dollé F, Hantraye P, Kirik D.

PLoS One. 2014 Mar 10;9(3):e90759. doi: 10.1371/journal.pone.0090759. eCollection 2014.

25.

Global optogenetic activation of inhibitory interneurons during epileptiform activity.

Ledri M, Madsen MG, Nikitidou L, Kirik D, Kokaia M.

J Neurosci. 2014 Feb 26;34(9):3364-77. doi: 10.1523/JNEUROSCI.2734-13.2014.

26.

Optogenetic inhibition of chemically induced hypersynchronized bursting in mice.

Berglind F, Ledri M, Sørensen AT, Nikitidou L, Melis M, Bielefeld P, Kirik D, Deisseroth K, Andersson M, Kokaia M.

Neurobiol Dis. 2014 May;65:133-41. doi: 10.1016/j.nbd.2014.01.015. Epub 2014 Jan 31.

PMID:
24491965
27.

Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease.

Moloney TC, Hyland R, O'Toole D, Paucard A, Kirik D, O'Doherty A, Gorman AM, Dowd E.

CNS Neurosci Ther. 2014 Jan;20(1):50-8. doi: 10.1111/cns.12200. Epub 2013 Nov 27.

28.

LAMP2A as a therapeutic target in Parkinson disease.

Xilouri M, Brekk OR, Kirik D, Stefanis L.

Autophagy. 2013 Dec;9(12):2166-8. doi: 10.4161/auto.26451. Epub 2013 Oct 8.

PMID:
24145820
29.

Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease.

Cederfjäll E, Nilsson N, Sahin G, Chu Y, Nikitidou E, Björklund T, Kordower JH, Kirik D.

Sci Rep. 2013;3:2157. doi: 10.1038/srep02157.

30.

Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration.

Xilouri M, Brekk OR, Landeck N, Pitychoutis PM, Papasilekas T, Papadopoulou-Daifoti Z, Kirik D, Stefanis L.

Brain. 2013 Jul;136(Pt 7):2130-46. doi: 10.1093/brain/awt131. Epub 2013 Jun 11.

PMID:
23757764
31.

Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors.

Hall H, Jewett M, Landeck N, Nilsson N, Schagerlöf U, Leanza G, Kirik D.

PLoS One. 2013 May 21;8(5):e64844. doi: 10.1371/journal.pone.0064844. Print 2013.

32.

Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease.

Hult Lundh S, Nilsson N, Soylu R, Kirik D, Petersén Å.

Hum Mol Genet. 2013 Sep 1;22(17):3485-97. doi: 10.1093/hmg/ddt203. Epub 2013 May 22.

PMID:
23697793
33.

Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra.

Reyes S, Cottam V, Kirik D, Double KL, Halliday GM.

Mov Disord. 2013 Sep;28(10):1351-9. doi: 10.1002/mds.25493. Epub 2013 May 14.

PMID:
23674405
34.

Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease.

Febbraro F, Sahin G, Farran A, Soares S, Jensen PH, Kirik D, Romero-Ramos M.

Neurobiol Dis. 2013 Aug;56:47-58. doi: 10.1016/j.nbd.2013.03.014. Epub 2013 Apr 5. Erratum in: Neurobiol Dis. O 2013 Oct;58:191.

PMID:
23567651
35.

The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats.

Mulcahy P, O'Doherty A, Paucard A, O'Brien T, Kirik D, Dowd E.

Behav Brain Res. 2013 Apr 15;243:6-15. doi: 10.1016/j.bbr.2012.12.051. Epub 2013 Jan 4.

PMID:
23295396
36.

Development of NMR spectroscopic methods for dynamic detection of acetylcholine synthesis by choline acetyltransferase in hippocampal tissue.

Hall H, Cuellar-Baena S, Denisov V, Kirik D.

J Neurochem. 2013 Feb;124(3):336-46. doi: 10.1111/jnc.12025. Epub 2012 Oct 10.

37.

Transduced wild-type but not P301S mutated human tau shows hyperphosphorylation in transgenic mice overexpressing A30P mutated human alpha-synuclein.

Oksman M, Wisman LA, Jiang H, Miettinen P, Kirik D, Tanila H.

Neurodegener Dis. 2013;12(2):91-102. doi: 10.1159/000341596. Epub 2012 Aug 30.

PMID:
22948283
38.

Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease.

Reyes S, Fu Y, Double KL, Cottam V, Thompson LH, Kirik D, Paxinos G, Watson C, Cooper HM, Halliday GM.

Neurobiol Aging. 2013 Mar;34(3):873-86. doi: 10.1016/j.neurobiolaging.2012.07.019. Epub 2012 Aug 24.

PMID:
22926168
39.

Introduction: gene therapy has gone from a pipe dream to clinical reality.

Kordower JH, Kirik D.

Neurobiol Dis. 2012 Nov;48(2):151-2. doi: 10.1016/j.nbd.2012.07.014. Epub 2012 Jul 20. No abstract available.

PMID:
22841531
40.

Animal models of Parkinson's disease: limits and relevance to neuroprotection studies.

Bezard E, Yue Z, Kirik D, Spillantini MG.

Mov Disord. 2013 Jan;28(1):61-70. doi: 10.1002/mds.25108. Epub 2012 Jul 2. Review.

41.

Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.

Gabery S, Sajjad MU, Hult S, Soylu R, Kirik D, Petersén Å.

Eur J Neurosci. 2012 Sep;36(6):2789-800. doi: 10.1111/j.1460-9568.2012.08193.x. Epub 2012 Jun 25.

PMID:
22731249
42.

Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons.

Ulusoy A, Björklund T, Buck K, Kirik D.

Neurobiol Dis. 2012 Sep;47(3):367-77. doi: 10.1016/j.nbd.2012.05.012. Epub 2012 May 31.

PMID:
22659302
43.

α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease.

Lastres-Becker I, Ulusoy A, Innamorato NG, Sahin G, Rábano A, Kirik D, Cuadrado A.

Hum Mol Genet. 2012 Jul 15;21(14):3173-92. doi: 10.1093/hmg/dds143. Epub 2012 Apr 18.

PMID:
22513881
44.

Altered profile of basket cell afferent synapses in hyper-excitable dentate gyrus revealed by optogenetic and two-pathway stimulations.

Ledri M, Nikitidou L, Erdelyi F, Szabo G, Kirik D, Deisseroth K, Kokaia M.

Eur J Neurosci. 2012 Jul;36(1):1971-83. doi: 10.1111/j.1460-9568.2012.08080.x. Epub 2012 Apr 18.

PMID:
22512307
45.

Long-term polarization of microglia upon α-synuclein overexpression in nonhuman primates.

Barkholt P, Sanchez-Guajardo V, Kirik D, Romero-Ramos M.

Neuroscience. 2012 Apr 19;208:85-96. doi: 10.1016/j.neuroscience.2012.02.004. Epub 2012 Feb 9.

PMID:
22342967
46.

Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease.

Cederfjäll E, Sahin G, Kirik D, Björklund T.

Mol Ther. 2012 Jul;20(7):1315-26. doi: 10.1038/mt.2012.1. Epub 2012 Jan 31.

47.

GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area.

Reyes S, Fu Y, Double K, Thompson L, Kirik D, Paxinos G, Halliday GM.

J Comp Neurol. 2012 Aug 15;520(12):2591-607. doi: 10.1002/cne.23051.

PMID:
22252428
48.

Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone.

Mulcahy P, O'Doherty A, Paucard A, O'Brien T, Kirik D, Dowd E.

Neuroscience. 2012 Feb 17;203:170-9. doi: 10.1016/j.neuroscience.2011.12.011. Epub 2011 Dec 13.

PMID:
22198020
49.

Magnetic resonance spectroscopic methods for the assessment of metabolic functions in the diseased brain.

Hall H, Cuellar-Baena S, Dahlberg C, In't Zandt R, Denisov V, Kirik D.

Curr Top Behav Neurosci. 2012;11:169-98. doi: 10.1007/7854_2011_166.

PMID:
22076698
50.

Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 in the dopaminergic system.

Xilouri M, Kyratzi E, Pitychoutis PM, Papadopoulou-Daifoti Z, Perier C, Vila M, Maniati M, Ulusoy A, Kirik D, Park DS, Wada K, Stefanis L.

Hum Mol Genet. 2012 Feb 15;21(4):874-89. doi: 10.1093/hmg/ddr521. Epub 2011 Nov 10.

PMID:
22076440

Supplemental Content

Support Center